ACMR Stock Analysis: Acm Research | NASDAQ
Semiconductor Equipment & Materials | NASDAQ, USA | Market Cap: 3.698m USD | 12M Return: 25.6% | US00108J1097 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 75.3M
EPS Trend: -35.4%
Qual. Beats: 2
Rev. Trend: 97.6%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 8.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
ACM Research, Inc. (NASDAQ: ACMR) is a U.S.-headquartered designer and manufacturer of semiconductor capital equipment, founded in 1998 and based in Fremont, California. The company supplies both front-end wafer fabrication equipment (wet cleaning tools, electrochemical plating, furnaces, PECVD, and track platforms) and back-end advanced packaging tools (coaters, developers, photoresist strippers, scrubbers, wet etchers, and copper-plating systems) to customers primarily in Mainland China and other international markets.
ACM Research differentiates its offerings through proprietary cleaning technologies marketed under the SAPS, TEBO, Tahoe, and Ultra C brands, alongside its Ultra ECP plating and Ultra Track product lines. The company sells directly and through third-party representatives, serving semiconductor manufacturers and wafer assembly/packaging customers.
As a participant in the Semiconductor Materials & Equipment industry, ACM Research operates in a capital-intensive sector where equipment vendors typically sell to foundries, integrated device manufacturers, and outsourced semiconductor assembly and test (OSAT) firms. Its revenue mix is heavily weighted toward China, making it one of the more geographically concentrated equipment suppliers in the industry.
- China chip self-sufficiency boost drives equipment orders
- US export controls threaten concentrated China revenue base
- ECP and PECVD platforms gain major foundry adoption
| Net Income: 150.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.04 > 0.02 and ΔFCF/TA -2.67 > 1.0 |
| NWC/Revenue: 201.2% < 20% (prev 119.6%; Δ 81.69% < -1%) |
| CFO/TA -0.00 > 3% & CFO -6.60m > Net Income 150.2m |
| Net Debt (-1.10b) to EBITDA (265.0m): -4.16 < 3 |
| Current Ratio: 3.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (71.8m) vs 12m ago 6.48% < -2% |
| Gross Margin: 43.84% > 18% (prev 49.40%; Δ -5.56% > 0.5%) |
| Asset Turnover: 38.16% > 50% (prev 39.96%; Δ -1.80% > 0%) |
| Interest Coverage Ratio: 31.87 > 6 (EBIT TTM 243.2m / Interest Expense TTM 7.63m) |
| A: 0.61 (Total Current Assets 2.87b - Total Current Liabilities 786.3m) / Total Assets 3.40b |
| B: 0.13 (Retained Earnings 456.7m / Total Assets 3.40b) |
| C: 0.09 (EBIT TTM 243.2m / Avg Total Assets 2.72b) |
| D: 1.87 (Book Value of Equity 1.86b / Total Liabilities 994.1m) |
| Altman-Z'' = 7.03 = AAA |
| DSRI: 1.00 (Receivables 605.2m/477.4m, Revenue 1.04b/815.2m) |
| GMI: 1.13 (GM 49.40% / 43.84%) |
| AQI: 0.98 (AQ_t 0.04 / AQ_t-1 0.04) |
| SGI: 1.27 (Revenue 1.04b / 815.2m) |
| TATA: 0.05 (NI 150.2m - CFO -6.60m) / TA 3.40b) |
| Beneish M = -2.73 (Cap -4..+1) = A |
As of October 24, 2026, the stock is trading at USD 50.55 with a total of 929,216 shares traded. Over the past week, the price has changed by -4.80%, over one month by -37.34%, over three months by -42.83% and over the past year by +25.59%.
Current recommended Stop Loss: 44.80 (which is 11.4% or 1.2 ATR below the current price).
Acm Research has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy ACMR.
- StrongBuy: 6
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 115.3 | 128.2% |
P/E Trailing = 25.0472
P/E Forward = 30.2115
P/S = 3.5638
P/B = 3.0205
Revenue TTM = 1.04b USD
EBIT TTM = 243.2m USD
EBITDA TTM = 265.0m USD
Long Term Debt = 192.9m USD (from longTermDebt, last quarter)
Short Term Debt = 152.9m USD (from shortTermDebt, last quarter)
Debt = 357.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 8.41m
Net Debt = -1.10b USD (calculated: Debt 357.7m - CCE 1.46b)
Enterprise Value = 2.60b USD (3.70b + Debt 357.7m - CCE 1.46b)
Interest Coverage Ratio = 31.87 (Ebit TTM 243.2m / Interest Expense TTM 7.63m)
EV/FCF = -21.61x (Enterprise Value 2.60b / FCF TTM -120.1m)
FCF Yield = -4.63% (FCF TTM -120.1m / Enterprise Value 2.60b)
FCF Margin = -11.58% (FCF TTM -120.1m / Revenue TTM 1.04b)
Net Margin = 14.48% (Net Income TTM 150.2m / Revenue TTM 1.04b)
Gross Margin = 43.84% ((Revenue TTM 1.04b - Cost of Revenue TTM 582.9m) / Revenue TTM)
Gross Margin QoQ = 45.96% (prev 46.37%)
Tobins Q-Ratio = 0.76 (Enterprise Value 2.60b / Total Assets 3.40b)
Interest Expense / Debt = 2.13% (Interest Expense 7.63m / Debt 357.7m)
Taxrate = 11.25% (26.5m / 235.6m)
NOPAT = 215.9m (EBIT 243.2m * (1 - 11.25%))
Current Ratio = 3.66 (Total Current Assets 2.87b / Total Current Liabilities 786.3m)
Debt / Equity = 0.19 (Debt 357.7m / totalStockholderEquity, last quarter 1.86b)
Debt / EBITDA = -4.16 (Net Debt -1.10b / EBITDA 265.0m)
Debt / FCF = 9.18 (negative FCF - burning cash) (Net Debt -1.10b / FCF TTM -120.1m)
Total Stockholder Equity = 1.58b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.52% (Net Income 150.2m / Total Assets 3.40b)
RoE = 9.48% (Net Income TTM 150.2m / Total Stockholder Equity 1.58b)
RoCE = 13.68% (EBIT 243.2m / Capital Employed (Equity 1.58b + L.T.Debt 192.9m))
RoIC = 7.95% (NOPAT 215.9m / Invested Capital 2.71b)
WACC = 15.18% (E(3.70b)/V(4.06b) * Re(16.46%) + D(357.7m)/V(4.06b) * Rd(2.13%) * (1-Tc(0.11)))
Discount Rate = 16.46% (= CAPM, Blume Beta Adj.) -> capped to 12.54%
Shares (quarterly) Correlation: 89.67 | Cagr: 3.67%
[DCF] Fair Price = unknown (Cash Flow -120.1m)
EPS Correlation: -35.35 | EPS CAGR: -8.52% | SUE: 2.38 | # QB: 2
Revenue Correlation: 97.60 | Revenue CAGR: 26.86% | SUE: 1.72 | # QB: 2
EPS current Quarter (2026-09-30): EPS=0.52 | Chg30d=+7.81% | Revisions=-17% | Analysts=4
EPS current Year (2026-12-31): EPS=2.14 | Chg30d=-0.69% | Revisions=+50% | GrowthEPS=+32.9% | GrowthRev=+29.8%
EPS next Year (2027-12-31): EPS=2.94 | Chg30d=+1.64% | Revisions=+50% | GrowthEPS=+37.5% | GrowthRev=+29.2%
[Analyst] Revisions Ratio: +42% (up=7, down=2)